All issues > Volume 35(10); 1992

Original Article

J Korean Pediatr Soc. 1992;35(10):1355-1360. Published online October 15, 1992.

Growth Promoting Effect of Recombinant methionyl-Growth Hormone in Children with Chronic Renal Failure

Heon Seok HS Han¹, Yong Y Choi², Hyung Ro HR Moon²

¹Department of Pediatrics, Chonbuk National University Medical School, Cheongju, Korea
²Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea
²Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea

Abstract

The authors studied the growth-promoting effect of yeast-derived methionyl-hGH in short statured children with uremic chronic renal failure. The subjects were prepubertal chronic renal insufficient patients whose height standard deviation scores were below -2.0. Two boys and two girls participated in this study. Chronic renal insufficiency was the only cause for the short stature. HGH was given to the subjects in dose of 0.75 U/kg/wk subcutaneously in three divided doses for the first six months, and then in six divided doses for the next six months. The height, weight, complete blood count and blood chemistries were checked every 3 months, and bone age, thyroid functions, IGF-1 and growth hormone antibody were tested every 6 months. The mean height SDS before treatment, at 6 months, and at 12 months of therapy was -4.43, -4.42 and -4.05, respectively. The height velocity before therapy, at 6 months and at 12 mo of therapy was 2.68, 5.43 and 5.90 cm/yr, respectively. The height velocity differences were -2.05 before therapy, +1.43 at 6 mo, +1.60 cm/yr at 12 mo of therapy. The mean bone age advancement was 0.9 yr in a year of therapy. The growth hormone antibody was not detected during therapy with the preparation. These results suggest that administration of yeast-derived methiony-hGH is effective in promoting linear growth for the short statured uremic prepubertal children.

Keywords :Human growth hormone, Chronic renal failure, Short stature